BFRI
Biofrontera Inc

8,674
Mkt Cap
$9.09M
Volume
515,981.00
52W High
$1.19
52W Low
$0.536
PE Ratio
-0.43
BFRI Fundamentals
Price
$0.7699
Prev Close
$0.78
Open
$0.832
50D MA
$0.8216
Beta
0.64
Avg. Volume
432,974.75
EPS (Annual)
-$3.22
P/B
-3.52
Rev/Employee
$401,301.08
$5.02
Loading...
Loading...
News
all
press releases
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biofrontera Inc. (BFRI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?
Here is how Biofrontera Inc. (BFRI) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Zacks·6d ago
News Placeholder
Biofrontera Earnings Preview
read more...
Benzinga·3mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -3.70% and -75.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +116.81% and +20.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest BFRI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.